Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

by Ann Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, Wattana Sukeepaisarnjaroen, Tsai Shen Yang, Cheng Chung Wu, Yee Chao, Stephen L. Chan, Masatoshi Kudo, Masafumi Ikeda, Yoon Koo Kang, Hongming Pan, Kazushi Numata, Guohong Han, Binaifer Balsara, Yong Zhang, Ana Marie Rodriguez, Yi Zhang, Yongyu Wang, Ronnie T.P. Poon
Published 2018

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

by Daniel V. T. Catenacci, Yoon-Koo Kang, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard S. Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A. Marrone, Ronan J. Kelly, Rosalyn A. Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I. Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A. Moore, Minori Koshiji Rosales, Haeseong Park
Published 2023